Eventually, the approaches presented in this study may lead to the development of more advanced apolipoprotein mimetic peptides that could be used in the treatment of different metabolic disorders, such as dyslipidemia and LCAT deficiencies (69, 70). Here, LCAT is linked to metabolic syndrome.